inVentiv Health, the US-based provider of clinical development, commercialisation and consulting services, has boosted its capacity to recruit investigators for clinical research by teaming up with Medikly, a cloud-based platform for physician engagement.
Medikly’s multi-channel digital technology can help pharmaceutical companies to identify, engage with and retain investigators by “applying a real-time view of doctors based on their preferences and behaviours online”, InVentiv Health explained.
That includes insights into the physician’s specific areas of interest, preferred mode(s) of communication and influence within his or her community.
Sponsors can identify physicians likely to be interested in acting as investigators based on “work and characteristics that predispose them to research or to recommend patients for a trial”, InVentiv Health noted.
The Medikly technology also enables trial sponsors to create communities for investigators, develop medical education programmes and apply engagement metrics to understand how healthcare providers will respond to messages.
In addition, sponsors can expand awareness of clinical, trials, build trust with physicians and accelerate acquisition rates, InVentiv Health said.
“By now, we all know that digital technologies can streamline clinical trials and save costs, but the challenge is knowing which technologies to use and how to best deploy them to save the most money and time,” commented Raymond Hill, president of clinical for inVentiv Health.
“This takes a special kind of expertise, grounded in broad global experience and deep insights into every aspect of drug development,” Hill added.
“inVentiv Health has that expertise and it is what drives our investment in technologies like Medikly to accelerate clinical trial success.”
Medikly’s primary focus is on pharmaceutical product marketing. However, its partnership with inVentiv Health gives the latter exclusive access to their platform and data-collection tools to use in clinical-trial recruitment.
More to come
As inVentiv Health pointed out, earlier this year it took an equity stake in clinical technology and services specialist Mytrus, which has launched the first electronic informed-consent technology to be endorsed by the US Food and Drug Administration.
“Additional partnership announcements are planned for the coming weeks,” inVentiv Health said.